Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab with Enzalutamide +/- Abiraterone in mCRPC
NCT02758132Phase 2Terminated
- Sponsor
- University of Hawaiʻi
- Start
- Mar 2016
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of abiraterone in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by University of Hawaiʻi. Primary endpoint: Change in Serum-based Metabolites Associated With Bone Deposition, Growth and Turnover. Started Mar 2016; status: terminated.
02
Drugs
abiraterone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02758132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02758132.